Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Antiviral Res. 2023 May 9;217:105620. doi: 10.1016/j.antiviral.2023.105620

Table 3.

Approved drugs with active assay results found in SMACC.

Compound Information Active Assay Results in SMACC

Drug name Brand name Approved clinical use Inhibitory MOA ChEMBL ID Phenotypic Assay Target-Based Assay
Simeprevir Olysio® HCV NS3/NS4B Protease CHEMBL501849 H7N7 Matrix Protein 2
Asunaprevir Sunvepra® HCV Protease CHEMBL2105735 H7N7 Matrix Protein 2
Sofosbuvir Sovaldi® HCV NS5B CHEMBL1259059 Dengue Virus
Ribavirin Copegus® HCV, RSV, fever RdRp CHEMBL1643 HPIV-3, Sandfly Fever, Dengue Virus, Yellow Fever Virus, RSV
Lopinavir Kaletra® HIV Protease CHEMBL729 SARS-CoV-2
Nelfinavir Viracept® HIV Protease CHEMBL584 Dengue Virus
Raltegravir Isentress® HIV Integrase CHEMBL254316 H7N7 Matrix Protein 2
Elvitegravir Vitekta ® HIV Integrase CHEMBL204656 SARS-CoV-2 3CLpro
Atazanavir Reyataz® HIV Protease CHEMBL1163 SARS-CoV-2 3CLpro
Rilpivirine Edurant® HIV-1 Nonnucleoside reverse transcriptase CHEMBL175691 SARS-CoV-2
Podofilox Condylox® HPV-related diseases Cytotoxicity/cell division CHEMBL61 SARS-CoV-2
Trifluridine Viroptic® HSV Viral and cellular DNA synthesis CHEMBL1129 HPIV-3
Idoxuridine Dendrid® HSV-1 Viral and cellular DNA synthesis CHEMBL788 Zika NS5
Acyclovir Zovirax ® HSV, VZV Viral DNA polymerase CHEMBL184 H7N7 Neuraminidase
Zanamivir Relenza® Influenza A and B Neuraminidase CHEMBL222813 H7N7